Loading…
Samrat Pharmachem (BSE 530125)₹257.95−0.02%Pharmaceuticals
In the Mar 2026 quarter (standalone), Samrat Pharmachem reported sales of ₹71.54 Cr, up 0.7% from Mar 2025, and net profit of −₹2.05 Cr. For the year to Mar 2026, sales were ₹289 Cr and net profit −₹3.01 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57.30 | 79.55 | 61.45 | 82.45 | 80.55 | 69.91 | 63.48 | 71.02 | 75.45 | 78.63 | 63.22 | 71.54 |
| Expenses | 56.80 | 79.67 | 61.67 | 81.47 | 78.43 | 66.89 | 59.65 | 71.25 | 75.71 | 79.39 | 64.20 | 73.19 |
| Operating Profit | 0.78 | 0.24 | 0.12 | 1.37 | 2.59 | 3.38 | 4.19 | 0.14 | 0.14 | −0.37 | −0.66 | −1.25 |
| OPM % | 1.3% | 0.3% | 0.2% | 1.6% | 3.2% | 4.8% | 6.6% | 0.2% | 0.2% | −0.5% | −1.0% | −1.7% |
| Other Income | 0.35 | 0.29 | 0.41 | 0.29 | 0.58 | 0.48 | 0.00 | −0.10 | 0.68 | 0.04 | 0.39 | −0.30 |
| Interest | 0.23 | 0.14 | 0.24 | 0.12 | 0.20 | 0.18 | 0.11 | 0.23 | 0.45 | 0.27 | 0.14 | 0.15 |
| Depreciation | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.16 | 0.16 | 0.15 | 0.16 | 0.17 | 0.18 | 0.18 |
| Profit before tax | 0.74 | 0.23 | 0.13 | 1.38 | 2.81 | 3.51 | 3.89 | −0.35 | 0.20 | −0.74 | −0.56 | −1.87 |
| Tax % | 18.6% | 174.9% | −142.9% | 0.0% | 26.6% | 24.4% | 28.9% | 11.1% | 209.4% | −21.4% | −19.4% | 8.5% |
| Net Profit | 0.62 | −0.20 | 0.35 | 1.41 | 2.08 | 2.67 | 2.79 | −0.41 | −0.24 | −0.60 | −0.47 | −2.05 |
| EPS (Rs) | 1.98 | −0.62 | 1.11 | 4.54 | 6.73 | 8.64 | 9.04 | −1.30 | −0.75 | −1.92 | −1.50 | −6.62 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 62.77 | 72.78 | 92.64 | 111 | 137 | 178 | 221 | 310 | 281 | 285 | 289 | 289 |
| Expenses | 62.10 | 69.10 | 87.23 | 108 | 131 | 170 | 197 | 288 | 280 | 277 | 293 | 292 |
| Operating Profit | 1.01 | 4.01 | 6.01 | 3.01 | 7.02 | 9.02 | 24.06 | 24.07 | 2.01 | 10.03 | −2.01 | −2.14 |
| OPM % | 1.9% | 5.0% | 6.0% | 2.9% | 4.8% | 4.8% | 11.0% | 8.0% | 0.9% | 3.6% | −0.7% | −0.7% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 | 0.99 | 0.00 | 0.99 | 0.99 | 0.99 | 0.81 |
| Interest | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.69 |
| Profit before tax | 0.00 | 2.99 | 4.98 | 1.99 | 5.98 | 6.98 | 23.93 | 22.92 | 2.99 | 9.97 | −2.99 | −2.97 |
| Tax % | 33.0% | 37.0% | 34.9% | 29.0% | 27.0% | 26.9% | 27.0% | 26.0% | 14.0% | 28.0% | 11.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 | 0.00 | — |
| Net Profit | 0.00 | 2.01 | 3.01 | 2.01 | 4.01 | 5.01 | 17.02 | 17.03 | 2.01 | 7.01 | −3.01 | −3.36 |
| EPS (Rs) | 0.98 | 5.68 | 10.46 | 5.00 | 13.78 | 17.31 | 55.86 | 54.04 | 7.01 | 23.10 | −10.75 | −10.79 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.0% | 2.0% | 13.9% | 4.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 |
| Reserves | 10.02 | 11.02 | 12.02 | 15.03 | 17.02 | 21.03 | 27.03 | 44.07 | 60.13 | 62.12 | 69.13 | 65.15 |
| Borrowings | 2.99 | 5.99 | 6.99 | 8.99 | 6.99 | 8.99 | 8.99 | 7.99 | 18.97 | 7.99 | 9.98 | 10.99 |
| Other Liabilities | 10.02 | 17.01 | 13.98 | 12.99 | 13.98 | 25.00 | 19.01 | 30.00 | 34.85 | 47.86 | 39.95 | 45.87 |
| Total Liabilities | 26.02 | 36.01 | 35.98 | 41.00 | 39.98 | 58.01 | 57.02 | 85.05 | 117 | 122 | 122 | 124 |
| Fixed Assets | 7.01 | 7.01 | 7.01 | 7.01 | 7.01 | 7.01 | 9.01 | 10.01 | 11.01 | 11.01 | 10.01 | 12.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 |
| Investments | 0.00 | 1.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.99 | 2.99 | 3.99 | 3.98 |
| Other Assets | 19.01 | 27.01 | 28.97 | 33.99 | 32.97 | 50.01 | 48.01 | 75.04 | 104 | 108 | 107 | 108 |
| Inventories | 4.01 | 6.02 | 7.02 | 7.02 | 8.03 | 19.07 | 11.04 | 12.04 | 33.09 | 21.08 | 38.11 | 44.11 |
| Trade receivables | 10.02 | 16.03 | 12.04 | 22.06 | 21.05 | 28.05 | 33.11 | 44.14 | 52.13 | 69.13 | 57.10 | 51.11 |
| Cash & equivalents | 3.99 | 3.99 | 1.99 | 3.99 | 1.99 | 0.99 | 2.99 | 14.96 | 11.98 | 9.97 | 0.00 | 5.99 |
| Total Assets | 26.02 | 36.01 | 35.98 | 41.00 | 39.98 | 58.01 | 57.02 | 85.05 | 117 | 122 | 122 | 124 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −1.01 | 0.00 | −3.01 | 0.00 | 2.01 | −1.01 | 5.01 | 17.03 | −9.02 | 9.01 | −10.02 | 9.02 |
| Cash from investing activity | 0.00 | −2.01 | 1.01 | −2.01 | 2.01 | −2.01 | −3.01 | −1.01 | −3.01 | 0.00 | 0.00 | −3.01 |
| Cash from financing activity | 0.00 | 2.01 | 1.01 | 2.01 | −4.01 | 2.01 | −2.01 | −2.01 | 10.02 | −11.03 | 0.00 | 0.00 |
| Net cash flow | 0.00 | 0.00 | −0.99 | −0.99 | 0.99 | −0.99 | 0.00 | 13.94 | −2.99 | −1.99 | −9.96 | 5.98 |
| Capex | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | 1.01 | 3.01 | 1.01 | 1.01 | 1.01 | 1.01 | 0.00 |
| Free cash flow | −0.99 | −0.99 | −3.99 | 0.00 | 1.99 | −2.99 | 2.99 | 15.95 | −10.97 | 8.97 | −10.97 | 5.98 |
| CFO / OP % | −29.0% | −25.0% | −73.0% | 17.0% | 126.0% | −7.0% | 81.0% | 78.0% | 0.0% | 503.0% | −84.0% | −489.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 73 | 92 | 58 | 85 | 68 | 73 | 66 | 71 | 60 | 89 | 71 | 63 |
| Inventory days | 38 | 37 | 41 | 31 | 28 | 55 | 25 | 24 | 43 | 28 | 52 | 56 |
| Days payable | 76 | 104 | 43 | 46 | 45 | 67 | 39 | 45 | 42 | 65 | 53 | 55 |
| Cash conversion cycle | 37 | 27 | 59 | 71 | 53 | 62 | 54 | 52 | 63 | 54 | 72 | 67 |
| Working capital days | 18 | 13 | 33 | 31 | 36 | 38 | 35 | 31 | 39 | 46 | 67 | 52 |
| ROCE % | 7.0% | 5.0% | 16.0% | 23.0% | 12.0% | 22.0% | 24.0% | 52.0% | 35.0% | 3.0% | 13.0% | −3.0% |
For the Mar 2026 quarter, Samrat Pharmachem reported sales of ₹71.54 Cr, up 0.7% year on year and net profit of −₹2.05 Cr. The operating margin was −1.7%.
Samrat Pharmachem's sales for the year to Mar 2026 were ₹289 Cr; over the last twelve months they were ₹289 Cr.
Net profit for the year to Mar 2026 was −₹3.01 Cr, and −₹3.36 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−10.79.
Samrat Pharmachem reported borrowings of ₹10.99 Cr at Mar 2026, against cash and equivalents of ₹5.99 Cr.
Cash from operations was ₹9.02 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹5.98 Cr.